China (Mainland)
Assessedsupplier
H-HIS-ALA-GLU-GLY-THR-PHE-THR-SER-ASP-VAL-SER-SER-TYR-LEU-GLU-GLY-GLN-ALA-ALA-LYS-GLU-PHE-ILE-ALA-TRP-LEU-VAL-LYS-GLY-ARG-GLY-OH CAS NO.106612-94-6
- Min.Order: 1 Gram
- Payment Terms: T/T
- Available Specifications:
- Product Details
Keywords
- GLP-1
- Glucagon like peptide 1 (7-37)
- Glucagon-relatedpeptide 1 (Rana catesbeiana), 3-L-glutamicacid-10-L-valine-16-glycine-17-L-glutamine-23-L-isoleucine-24-L-alanine-27-L-valine-31-glycine-32-de-L-lysine-
Quick Details
- ProName: H-HIS-ALA-GLU-GLY-THR-PHE-THR-SER-ASP-...
- CasNo: 106612-94-6
- Molecular Formula: C151H228N40O47
- Appearance: white powder
- Application: 106612-94-6
- DeliveryTime: in stock
- PackAge: according to the customer
- Port: shanghai
- ProductionCapacity: 1 Gram/
- Purity: 98
- Storage: room
- Transportation: by sea air and courier
- LimitNum: 1 Gram
- Related Substances: 1
- Residue on Ignition: 1
- Heavy Metal: 1
- Valid Period: 1
- 1: 1
- 1: 1
Superiority
| lucagon-Like Peptide 1 Fragment 7-37 human (GLP-1-(7-37)) interacts with the GLP-1 receptor (GLP-1r). It mediates insulin release by stimulating the cyclic AMP accumulation in islet cells GLP-l(7-37) is a potential therapeutic agent due to its insulin-secretagogue functionality. | |
| in vitro | In vitro, truncated glucagon-like peptides [GLP-1(7-36)-amide and GLP-1(7-37)] increase insulin secretion in a glucose-dependent manner, and desensitization to the action of GLP-1(7-37) has been demonstrated acutely with high concentrations. |
| in vivo | GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats. Infusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused |
Details
| lucagon-Like Peptide 1 Fragment 7-37 human (GLP-1-(7-37)) interacts with the GLP-1 receptor (GLP-1r). It mediates insulin release by stimulating the cyclic AMP accumulation in islet cells GLP-l(7-37) is a potential therapeutic agent due to its insulin-secretagogue functionality. | |
| in vitro | In vitro, truncated glucagon-like peptides [GLP-1(7-36)-amide and GLP-1(7-37)] increase insulin secretion in a glucose-dependent manner, and desensitization to the action of GLP-1(7-37) has been demonstrated acutely with high concentrations. |
| in vivo | GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats. Infusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused |